Cosmo Pharmaceuticals announced promising results for its experimental drug 'Classoterone', which could become the first innovative treatment for male pattern baldness in three decades. Advanced clinical trials involving about 1500 men showed significant efficacy, with one trial recording a 539% improvement in hair growth compared to a placebo, and another trial showing a 168% improvement. The drug works as a topical treatment for the scalp by inhibiting androgen receptors, thereby reducing the effect of male hormones that cause hair loss.
